Health News

11 Feb 2009 03:00 AM

Genentech Urges Shareholders To Take No Action With Respect To Unsolicited Tender Offer From Roche
The special committee of the Board of Directors of Genentech, Inc. (NYSE:DNA) urged Genentech shareholders to take no action at this time with respect to the tender offer commenced by Roche to acquire all of the outstanding shares of Genentech stock not owned by Roche at a price of $86.50 in cash per share. Currently, Roche owns approximately 55.8% of the outstanding shares of Genentech.

The special committee intends to take a formal position regarding the Roche offer within ten business days, and will explain in detail its reasons for that position by filing a Statement on Schedule 14D-9 with the Securities and Exchange Commission. The special committee members are Herbert W…
To see status of your order and get your bonus pills
(9:00 am – 5:00 pm ET)

Call Toll-free: 1–800–775–4570

Your email

Your birthday